Keyoung Hansoo Michael 4
4 · Kairos Pharma, LTD. · Filed Nov 26, 2025
Insider Transaction Report
Form 4
Keyoung Hansoo Michael
Director
Transactions
- Award
COMMON STOCK
2025-09-16+10,000→ 10,000 total - Award
COMMON STOCK
2025-10-08+19,084→ 29,084 total
Footnotes (4)
- [F1]Represents 10,000 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan (the "Plan"). The 10,000 RSUs were granted on September 16, 2024, in conjunction with the Issuer's initial public offering (IPO), and grant in substantially equal installments on the anniversary date of the IPO.
- [F2]Consists of (i) 3,334 shares of common stock and (ii) 6,666 RSUs which remain subject to vesting.
- [F3]Represents 19,084 RSUs) issued to the Reporting Person under the Plan. The 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date.
- [F4]Consists of (i) 3,334 shares of common stock and (ii) 25,750 RSUs which remain subject to vesting.